Eight-year experience with cryopreserved arterial homografts for the in situ reconstruction of abdominal aortic infections  by Bisdas, Theodosios et al.
Eight-year experience with cryopreserved arterial
homografts for the in situ reconstruction of
abdominal aortic infections
Theodosios Bisdas, MD,a Martin Bredt, MD,b Maximilian Pichlmaier, MD,a Thomas Aper, MD,a
Mathias Wilhelmi, MD,a Sotirios Bisdas, MD,c Axel Haverich, MDa and
Omke E. Teebken, MD,a Hannover and Tuebingen, Germany
Objective: This study investigated short-term and long-term outcomes in patients with abdominal aortic infection
(mycotic aneurysm, prosthetic graft infection, aortoenteric fistula) managed by total excision of the aneurysm or the
infected vascular graft and in situ aortic reconstruction with a cryopreserved arterial homograft (CAH).
Methods: From January 2000 to December 2008, 110 consecutive patients underwent CAH implantation for treatment of
vascular infections. In 57 (52%), in situ revascularization of the abdominal aorta with Y-prosthesis constructed from
CAHs was performed. Early outcome included 30-day mortality and the levels of daily blood markers (leucocytes,
C-reactive protein, and platelets) during the postsurgical 10-day period. We reported long-term survival and freedom
from reoperation rates, including all indications for reoperation.
Results: Indications for operation were infected vascular graft in 31 patients (55%), aortodigestive fistulae in 11 (19%),
nonruptured mycotic aneurysms in 4 (7%), and ruptured mycotic aneurysms of abdominal aorta in 11 (19%). In 39 of 57
patients (68%), the intraoperative specimens were positive for at least one microorganism, and Staphylococcus aureus was
present in 14 (25%). In 32 patients (82%) with intraoperative specimens positive for microorganisms, there was no
evidence of the intraoperatively detected microorganisms in the postoperative specimens (wound, blood culture, and
drainage fluid). The peak value of leucocytes (13.7  4.4  103/L) and C-reactive protein (200  75 mg/L) occurred
on postoperative day 3. Platelets reached the lowest value on postoperative day 2 (178 67 109/L). Median peak body
temperature was 37.7° 0.6°C. Thirty-daymortality was 9% (5 of 57 patients).Median follow-up was 36months (range,
4-118months); 3-year survival was 81%, and freedom from reoperation was 89%. Five patients (9%) required reoperation,
in one patient each for postoperative bleeding, acute cholecystitis, homograft occlusion, homograft-duodenum fistula,
and aneurysmal degeneration. No recurrence of infection was reported.
Conclusion: These results demonstrate an encouraging outcome after cryopreserved allograft implantation for the
treatment of vascular infections in the abdominal aorta. The data represent a basis for future comparisons with other
treatment modalities for vascular infections, including silver-coated prostheses and autogenous femoral veins. ( J Vasc
Surg 2010;52:323-30.)Vascular graft infection remains one of the most chal-
lenging complications in vascular surgery, with an inci-
dence of 0.5% to 3.5%,1-3 and is certainly higher due to
insufficient follow-up and lack of information about late or
recurrent infections.3,4 The high incidence and mortality
rates of vascular graft infection make the establishment of a
standard treatment mandatory.5
Extra-anatomic bypass has long been the therapy of
choice for graft infection.6,7 As an alternative therapeutic
strategy, however, several centers have proposed the total
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doi:10.1016/j.jvs.2010.02.277excision of the infected prosthesis and the in situ arterial
reconstruction with an infection-resistant graft. Various
substitute materials, including autogenous veins, cryopre-
served arterial homografts (CAH), and rifampicin-bonded,
amikacin-loaded, or silver-coated prostheses have been de-
veloped in an attempt to provide the most effective eradi-
cation of the infection focus and to prevent the recurrence
of any infection.
All types of materials and techniques have been asso-
ciated with different rates of complications, including
graft failure, hemorrhage, thrombosis, and infection rec-
curence.7-10 Encouraging but still controversial results
have been established after implantation of CAHs for in situ
arterial reconstruction.8-12 CAHs have been already evalu-
ated in patients undergoing aortic valve replacement
against endocarditis, with excellent clinical outcome.13
Advanced methods of cryopreservation and decontam-
ination of homografts have resulted in better graft survival,
namely regarding the viscoelastic and inertial properties of
the arterial wall.14 Although the results after homograft
implantation have been well-documented in recent years,
the ongoing evaluation of their efficacy remains necessary
due to the absence of any randomized trials or level I
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experience by reporting the short-term and long-term out-
comes after in situ reconstruction of the abdominal aorta
with CAH due to vascular infection.
MATERIALS AND METHODS
Patients. A retrospective review of our prospectively
maintained database for vascular infections from January
2000 to December 2008 indicated 138 patients underwent
an operation due to vascular infection. Of these, 110 (80%)
received CAH and 28 (20%) received a silver-coated graft.
In situ reconstruction of the abdominal aorta with CAH
was preferred in 57 (51%). The remaining 53 patients
(49%), who underwent CAH-implantation elsewhere in the
aortic root or in the femoropopliteal vessels, were excluded
from this study to reduce heterogeneity of the population
and achieve more comparability to similar studies. Patient
demographics and comorbidities are listed in Table I.
Surgical technique. The infected abdominal aorta or
prosthetic graft was approached through a midline incision
and entirely excised. Bacteriologic culture tests were per-
formed on the periprosthetic fluid, the infected prosthetic
graft, or the infected aorta. All patients underwent com-
plete débridement of surrounding tissues, followed by irri-
gation of the operative fields with liberal amounts (2 L) of
7.5% standard povidone-iodine solution (Braunol, B
Braun, Melsungen AG, Germany) diluted in 0.9% isotonic
saline.
All CAH were irrigated with 5000 IU neomycin/250
IU bacitracin solution (Baneocin pro instillatione, Sandoz
GmbH, Kundl, Austria) for at least 5 minutes and im-
planted as an in situ replacement with polypropylene suture
for all anastomoses. Before blood flow was restored, the
outer surface of CAH and the adhering tissues were im-
pregnated with fibrin glue. In patients with aortoenteric
fistulas, the bowel defect was repaired with lateral closure or
bowel resection. The new prosthesis was covered with a
pedicled anterior omentoplasty when possible.
Homograft preparation. All homografts were pro-
vided by Deutsche Gesellschaft fuer Gewebetransplanta-
tion (or its predecessor DSO-G) and were harvested from
multiorgan donors. All donors were tested seronegative for
HIV, antibodies against hepatitis B surface and core anti-
gen, hepatitis C, and cytomegalovirus. Explants were ini-
tially stored in 4°C Ringer’s solution and were processed
according to standard operating procedures. Before and
after decontamination (M199 containing meropenem,
colistin, tobramycin, vancomycin, and amphotericin B at
4°C for 24 hours) microbiologic tests from various tissue
samples were performed.
Tissues were rinsed with tissue culture medium, trans-
ferred to M199 containing 10% dimethylsulfoxide as cryo-
protective agent, and frozen at –1°C per minute to –40°C.
Before the cryopreservation, various tissue samples were
examined by an independent pathologist according to an
internal protocol comparable to the standards of American
Association of Tissue Banks. Only high-quality homografts
without any pathologic changes were processed. After fur-ther cooling to –100°C, the homografts were transferred to
permanent storage in the vapor phase of liquid nitrogen.
Before implantation, grafts were thawed and washed in
three consecutive 40°C baths of Ringer’s solution in the
operating room.
Postoperative management and follow-up exam-
ination. Intravenous antibiotics were administered along
Table I. Patient comorbidities, indications for operation,
and intraoperatively detected microorganisms
Variable Patients No. (%)
Total 57
Gender
Male 50
Female 7
Comorbidity
COPD 7 (12)
Hypertension 50 (88)
Nicotine abuse 21 (37)
Coronary disease 21 (37)
Myocardial infarction 15 (26)
Hypercholesterolemia 11 (19)
Diabetes mellitus (type 1 or 2) 28 (49)
Renal failure 15 (26)
ASA score
I 0 (0)
II 12 (21)
III 34 (60)
IV 11 (19)
Indications for operation
Infected vascular graft 31 (55)
Aortodigestive fistula 11 (19)
Mycotic aneurysma
Ruptured 4 (7)
Nonruptured 11 (19)
Microorganisms detected intraop
No microorganisms 18 (32)
Staphylococcus aureus 14 (25)
Escherichia coli 8 (14)
MRSA 5 (9)
Pseudomonas aeruginosa 5 (9)
Staphylococcus epidermidis 5 (9)
Enterococcus faecalis 4 (7)
Enterobacter clocae 3 (5)
Enterococcus faecium 3 (5)
Staphylococcus haemolyticus 3 (5)
Streptococcus anginosus 3 (5)
Campylobacter fetus 2 (4)
Enterococcus spp 2 (4)
Bacteroides fragilis 1 (2)
Citrobacter freundii 1 (2)
Lactobacillus rhamnosus 1 (2)
Propionibacterium spp 1 (2)
Salmonella typhimurium 1 (2)
Staphylococcus coagulase-negative 1 (2)
Stenotrophomonas maltophilia 1 (2)
Streptococcus sanguinis 1 (2)
ASA, American Society of Anesthesiologists; COPD, chronic obstructive
pulmonary disease; MRSA, methicillin-resistant Staphylococcus aureus.
aAs mycotic aneurysms, we defined only those naturally occurring aortic
aneurysms that result from or are secondarily infected by bacteria or fungi
arising in a distant site of infection. The infection of the aneurysm was
suspected from blood or wound culture results, imaging findings and clinical
presentation in the absence of implanted prosthetic material.8,12with parenteral nutrition. Oral administration of culture-
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and adapted from endocarditis treatment guidelines.15 In
patients with methicillin-resistant Staphylococcus aureus
(MRSA) infection, we preferred the administration of lin-
ezolid instead of vancomycin.
All surviving patients underwent duplex scanning before
discharge from the hospital. Routine late follow-up after dis-
charge included clinical examinations and computed tomog-
raphy scans at 3 months and annually thereafter.
Study design and definitions. The criteria of the
Centers for Disease Control and Prevention (Atlanta, Ga)
were used to define evidence of infection in intraoperative
and postoperative microbiologic specimens, as well as the
primary sepsis that developed after implantation of the
CAH.16 All postoperative specimens from wounds, blood
cultures, and drainage fluids were recorded and matched
with the respective intraoperative findings to control the
effectiveness of the homograft to eliminate the responsible
agent(s).
In the early period, primary outcome was 30-day mor-
tality. The record of bloodmarkers of infection (leucocytes,
C-reactive protein [CRP]) and peak body temperature
during the first 10-day postsurgical period were secondary
outcomes. Platelets counts were also reported. We tracked
long-term survival and freedom from reoperation (FFR)
rates, including all indications for reoperation.
Statistical methods. All analyses and graphs were per-
formed with MedCalc 9.4.2.0 software (Mariakerke, Bel-
gium). A logistic regression analysis model with stepwise
method, including patient comorbidities and characteris-
tics, was designed to identify any prognostic factor associ-
ated with poor outcome. Survival and FFR rates were
calculated using Kaplan-Meier method. A value of P .05
was considered statistically significant. Where data points
were missing, the number of available observations was
reported, and no assumptions were made about the missing
data.
RESULTS
Indications and initial procedures. The indications
for operations are listed in Table I. In the group with vascular
graft infection, the initial prosthesis was made of polyester
fiber (Dacron) in 26 patients (84%), polytetrafluoroethylene
(PTFE) in 1 (3%), and silver-coated in 4 (13%). The mean
interval from the aortic graft insertion to the diagnosis of graft
infectionwas 42months (range, 0.5-180months). The oldest
graft (Dacron) was implanted in 1993, and the infection was
diagnosed 10 years later. In themeantime, this patient under-
went a myocardial revascularization.
Configurations of the infected aortic grafts were aor-
toaortic in 3 patients (10%), aortobiiliac in 13 (42%),
aortobifemoral in 10 (32%), and aortobiprofunda in 5
(16%). The intraoperatively administrated antibiotics were
ceftriaxone in 47 and linezolid in 10. Eight patients who
received vancomycin as their preoperative antibiotic were
given ceftriaxone concurrently.
Microbiologic findings. Intraoperative microbiolo-
gic specimens were obtained from all patients, and 39 of 57patients (68%) showed evidence of one or more microor-
ganisms. Table I presents the intraoperatively detected
microorganisms and their incidence, and the most com-
mon was Staphylococcus aureus (25%). In 32 of these 39
patients (82%), all postoperative microbiologic specimens
(bloodstream, wound, drainage fluid) were free from the
intraoperatively detected pathogen agent(s). An ongoing
infection in 7 of 39 patients (18%) resulted in positive
postoperative microbiologic cultures. Table II presents the
microbiologic findings and the postoperative course in
patients with ongoing infection postoperatively.
Early period. The primary outcome, 30-day mortal-
ity, was 9% (5 of 57 patients). Four patients died of sepsis-
related multiple organ failure, and one patient died of
hemorrhagic-septic shock. Postmortem examinations were
not performed. The logistic regression analysis model in-
cluding all comorbidities, age of patients, and American
Society of Anesthesiologists (ASA) score identified no spe-
cific prognostic factors for poor outcome during the in-
hospital stay.
Among the secondary outcomes, median hospital stay
was 21 days (range, 0-34 days). Median peak body temper-
ature during the in-hospital stay was 37.7°C (range, 37.1°-
38.3°C). Leucocytes and CRP levels reached their highest
values on postoperative day (POD) 3 (13.7 4.4 103/L
and 200  75 mg/L, respectively). The lowest value of
platelets was obtained on POD 2 (178 67 109/L). All
variables returned to preoperative values after POD 10 (Fig 1).
Late period. Median follow-up was 36 months
(range, 4-118months). Five patients (9%) refused to attend
any follow-up investigation, of whom one was an intrave-
nous drug addict. Postoperative survival and FFR rates are
illustrated as Kaplan-Meier curves in Fig 2. Survival and
FFR rates were 81% and 89% at 3 years and 64% and 89% at
Table II. Microbiologic findings and postoperative
course in patients with ongoing evidence of intraoperative
microorganisms in the postoperative microbiologic
specimens
Patient
Intraop
contamination of
surgical site
Postop
infection type
(CDC criteria) Postop course
1 Staphylococcus aureus BSI Dieda POD 19
2 Bacteroides fragilis BSI Died POD 3
3 Salmonella
typhymurium
BSI, OS-SSI Recovered
4 MRSA OS-SSI, SSI Recovered
5 MRSA BSI, OS-SSI Recovered
6 Enterococcus faecium SSI Recovered
7 Enterococcus faecalis SSI Died POD 11
Staphylococcus aureus
BSI, Bloodstream infection; CDC, Centers for Disease Control and Preven-
tion; MRSA, methicillin-resistant Staphylococcus aureus; OS-SSI, organ
space-surgical site infection; POD, postoperative day; SSI, surgical site
infection.
aAll patients died of sepsis-related multiple organ failure.5 years. Causes of death were myocardial infarct (n  3),
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and fatal stroke (n  1).
Five patients (9%) underwent reoperations:
● The first patient underwent operation on postopera-
tive day 2 through a repeat laparotomy due to a
postoperative bleeding.
● The second patient underwent thrombectomy and
transluminal angioplasty due to an occlusion of ho-
mograft on postoperative day 2.
● The third patient showed signs of acute cholecystitis
on postoperative day 2 and an emergency cholecystec-
tomy was necessary. No microorganisms were found
intraoperatively.
● In the fourth patient, a fistula between the duodenum
and the homograft was diagnosed 1 month postoper-
atively. A reconstruction of the right homograft
branch with a segment of the great saphenous vein was
performed.
● In the last patient, an aneurysmal degeneration of the
distal homograft anastomosis 2 years after the initial
operation required implantation of an aortoprofunda
Dacron bypass. At the time of reoperation, there were
no signs of contamination intraoperatively or in the
microbiologic specimens. Fig 3 represents the findings
of histopathologic examination of the aortic wall of the
degenerated homograft and compares its cellular
structure with a CAH before implantation.
None of these patients required other reoperations and
they are doing well. None was diagnosed with a recurrence
Fig 1. Levels for C-reactive protein (CRP), leucocytes,
shown in 57 patients undergoing cryopreserved arteria
vascular infection.of the initial infection.DISCUSSION
The gold standard of therapy for vascular infections is
still unknown. Controversial results for the different treat-
ment approaches have been reported. Only a few studies
have established results for long-term recurrence of infec-
tion and reoperation rates.7-10 A variety of techniques have
evolved in the treatment of aortic graft infection, each with
its own advantages and disadvantages.13 For example, after
débridement and aortic stump closure, extra-anatomic ax-
illobifemoral bypass is associated with significantly high
rates of reinfection, early thrombosis, and late graft fail-
ure.17 Rifampicin-bonded, amikacin-loaded, or silver-
coated prostheses are valuable alternatives but bear the risk
for infection recurrence, development of antibiotic resis-
tance, and graft failure or occlusion.17,18 Furthermore,
encouraging results after in situ repair of mycotic aneu-
rysms with femoral/popliteal veins have been published.19
Despite their resistance to infection and low rates of graft
failure, widespread use of these veins was prevented by
operation time and surgical trauma.
In the current study, we addressed the effectiveness of
CAHs in the treatment of vascular infections in an 8-year
period. To allow for better comparison with the literature,
we excluded cases of vascular infections limited to the lower
or upper limbs and even the iliac arteries because aortic
infections are prone to higher mortality. Furthermore, the
low number of patients undergoing in situ reconstruction
of the abdominal aorta with a silver-coated graft (20 of 28
patients) did not allow a valid comparison between the two
latelets during the first 10 postoperative days (POD) are
ografts implantation in the abdominal aorta due to aand p
l hommaterials. Noteworthy is that we preferred a silver-coated
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The main goals for the evaluation of CAH were the suc-
cessful elimination of the urgent sepsis and the prevention
of infection recurrence, as reflected in the early and late
outcomes, respectively.
Thirty-day mortality was 9%. Although our results are
comparable with other studies, the early mortality rate was
still high.7,9,10 However, considering the mortality risk of
these patients in terms of septicemia, comorbidities, and
severity of a reoperation in an infected environment, and
that 79% of our cohort was classified with an ASA score3,
Fig 2. Kaplan-Meier life-table analysis presents (A) s
cryopreserved arterial homografts replacement against va
interval is shown on both figures.we could argue that these outcomes are acceptable.The distribution of the blood markers during the first
10 PODs showed successful elimination of the infection.
Most patients recovered to preoperative values. CRP
showed a slight second increase between PODs 5 and 10
without a parallel increase of leucocytes. As suggested and
described in more detail in a previous study,20 these find-
ings may be explained by an immunologic response of the
recipient against the homograft triggered by an eventual
ABO mismatch, whereas the current literature remains
contradictory on this particular topic.20-22
None of the patients in the present study showed
l rates and (B) freedom from reoperation rates after
r infections in the abdominal aorta. The 95% confidenceurviva
sculaprolonged pyrexia. In addition, postoperative control ultra-
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accumulation or enhanced tissue formation around the
homograft. These findings often give cause for additional
diagnostic procedures if found after prosthetic graft re-
placement.23-25
An important confounder for the downscaling course
of blood markers was the administration of specific antibi-
otics according to the antibiogram after microbiologic in-
vestigation of the intraoperative specimens. Therefore, the
Fig 3. A, Histologic examination of the arterial wall from cryo-
preserved arterial homografts (CAH) before implantation show
slight edema of tunica intima and fibrosis (1), but the internal
elastic membrane is identifiable (2) as a thick line between the
tunica intima and media). The tunica media has low number of
elastic fibers, and the smooth muscle cells (SMCs) with their cores
are arranged in a normal spiral orientation around the long axis of
the vessel (Alcian blue stain, original magnification 100). B,
Histologic examination of a degenerated CAH 2 years after im-
plantation shows intraluminal thrombus (red material, 1), edema,
and fibrosis of the tunica intima, as well as atherosclerosis (foamy
cells, 2).Neither internal elastic membrane nor SMCs of the media
are identifiable, and multifocal destruction of the tunica media and
elastic fibers (not shown) has occurred (hematoxylin and eosin
stain; original magnification 100).careful gain of intraoperative specimens is indispensable forthe success of therapy. We have routinely administrated
ceftriaxone as an intraoperative antibiotic because of its
broad-spectrum activity against gram-positive and gram-
negative bacteria. Ceftriaxone was also the postoperative
antibiotic of choice in patients without evidence of micro-
organisms in their intraoperative specimens. In patients
with MRSA infection, we preferred linezolid instead of
vancomycin postoperatively. Several studies showed lin-
ezolid offered more effective eradication of MRSA, espe-
cially in soft tissue infections, and lower rates of renal
toxicity than vancomycin.26,27
The lowest mean value of platelets occurred on POD 2
but thereafter showed a continuing increase. Noteworthy is
the role of platelets during infection and their interaction
with bacterial pathogens. Such interactions have been cur-
rently reported and elucidated in patients with S aureus-
related endocarditis and infections with Streptococcus pneu-
moniae.28-31 Several significant gram-positive pathogens
have been shown to directly stimulate platelet activation.31
The activated platelets release antibacterial peptides that kill
the bacteria.29
The microbiologic investigation of the intraoperative
and postoperative specimens showed an encouraging erad-
ication of the responsible agent even in the presence of
virulent or traditionally difficult-to-treat organisms like
Pseudomonas aeruginosa or Stenotrophomonas maltophilia
(Table I). The intraoperative specimens in 32% of the
patients had no evidence of contamination. This finding
could be explained because the diagnosis of graft infection
initiates aggressive presurgical antibiotic therapy that can
lead to negative results for pathogenic organisms in the
intraoperative specimens. In 80% of patients with positive
results for microorganisms intraoperatively, there was no
evidence of the pathogenic agent(s) in the postoperative
specimens (wound, blood sample, and drainage fluid).
We believe an important factor, in addition to the
antibiotic treatment, is the impregnation of homograft with
neomycin before the implantation. Neomycin is an amino-
glycoside antibiotic with excellent activity against gram-
negative and partial activity against gram-positive bacte-
ria.32 By local administration, we aim to amplify the transfer
of the antibiotic to the perigraft tissues, to protect the
homograft from any colonization of microorganisms, and
to prevent any toxicity side effects of neomycin through the
patient’s gastrointestinal tract. No eczematous reactions,
renal insufficiency, or hearing loss developed in any of the
patients.
Patients with ongoing presence of the pathogenic mi-
croorganism in their postoperative specimens showed a
very high mortality rate of 43% (3 of 7 patients; Table II)
and died of sepsis-related multiple-organ failure. These
results highlight the changing epidemiology of infections:
bacteria such as S aureus, S epidermidis, and Enterococcus
faecalis are increasingly resistant to antibiotic therapy.3
The analysis of long-term results showed efficient
3-year survival of 81% and FFR of 89%. Similar findings
were presented by Kieffer et al,10 who documented 24%
late mortality and 89% 3-year FFR rates after implantation
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CAHs in the abdominal aorta. Comparably, Leséche et al9
found that survival was 67% and FFR was 83% after 3 years
of surveillance.
With respect to the different indications, comorbidities
of patients, and surgical procedures, our results are compa-
rable with current publications of alternative substitutes.
Oderich et al17 reported major complications or procedur-
ally related deaths in 60% of patients undergoing axil-
lofemoral bypass. Batt et al,33 in 24 patients undergoing an
in situ reconstruction with silver-coated polyester grafts,
reported 26% late mortality, and 37.5% of their patients
required early or late intervention due to graft reinfection.
None of the patients in our cohort underwent operations
due to a recurrence of the initial infection. Nevertheless,
subclinical persistent aortic graft infection during the long-
term cannot be assuredly excluded. In the framework of our
surveillance protocol, the patient undergoes no further
investigations (eg, fludeoxyglucose F 18 positron-emission
tomography or computed tomography scan) and takes no
antibiotics if there are no clinical, laboratory, microbio-
logic, and radiologic signs of infection.
In our opinion, the aneurysmal degeneration of the
distal anastomosis of homograft in one patient (1.7%) is
acceptable and should not discourage the vascular surgeon
from the use of CAH. However, CAH may degenerate in
the long-term, possibly due to an immune response or to
the imperfectness of current cryopreservation methods, or
both, and this is the major drawback of this therapy con-
cept.9,21,22 Future pharmaceutical developments and im-
provement of cryopreservation techniques may decelerate
the degeneration process and increase the durability of
homografts. In our cohort, we excluded any subclinical
aneurysmal degeneration during the surveillance period
through the regular performance of ultrasound imaging
and CT scans. The radiologic findings were evaluated sep-
arately by an independent radiologist and an experienced
vascular surgeon.
CONCLUSIONS
Despite the small size of our study population and the
retrospective design, we reported encouraging outcomes in
patients undergoing an in situ reconstruction of the ab-
dominal aorta with CAH because of a vascular infection.
Generalized sepsis was prevented in nearly all patients. In
addition, there was no recurrence of the initial infection in
the long-term follow-up, and the survival rates were accept-
able and comparable with previous studies. However, de-
generation, limited availability, and higher costs of CAH
still remain major drawbacks. Although we propose CAH
as a safe and efficient method for the treatment of vascular
infections of the abdominal aorta, we consider that a ran-
domized controlled study comparing the two most prom-
ising substitute materials against vascular infections—CAH
and silver-coated prostheses—is mandatory to serve our
patients even better in the near future.AUTHOR CONTRIBUTIONS
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